Avenue Therapeutics, Inc.
Other OTCTotal Valuation
Avenue Therapeutics, Inc. carries a market capitalization of 1.15M, placing it among publicly traded companies globally. Its enterprise value stands at -1.48M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.15M |
| Enterprise Value | -1.48M |
Share Statistics
Avenue Therapeutics, Inc. currently has 3.29M shares outstanding.
| Shares Outstanding | 3.29M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 0.67, and the price-to-book ratio stands at -0.01.
| PE Ratio | N/A |
| PS Ratio | 0.67 |
| PB Ratio | -0.01 |
| P/TBV Ratio | 0.78 |
| P/FCF Ratio | -0.86 |
| P/OCF Ratio | -0.86 |
Financial Position
Avenue Therapeutics, Inc. maintains a current ratio of 1.94, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.94 |
| Quick Ratio | 1.90 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -57.80 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 5.97 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Avenue Therapeutics, Inc.'s stock has gained approximately 34.61538% over the past 52 weeks. The 50-day moving average sits at 0.42, while the 200-day moving average is 0.54.
| Beta (5Y) | N/A |
| 52-Week Price Change | 34.61538% |
| 50-Day Moving Average | 0.42 |
| 200-Day Moving Average | 0.54 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Avenue Therapeutics, Inc. generated 1.40M in revenue and converted that into -1.75M in net income, yielding earnings per share of -0.55. EBITDA reached -2.10M, while operating income came in at -2.10M.
| Revenue | 1.40M |
| Gross Profit | N/A |
| Operating Income | -2.10M |
| Pretax Income | -1.78M |
| Net Income | -1.75M |
| EBITDA | -2.10M |
| EBIT | -2.10M |
| Earnings Per Share (EPS) | -0.55 |
Balance Sheet
Total book value stands at -106.18M, with working capital of 1.20M providing operational flexibility.
| Cash & Cash Equivalents | 2.42M |
| Total Debt | N/A |
| Net Debt | -2.42M |
| Equity (Book Value) | -106.18M |
| Book Value Per Share | -32.97 |
| Working Capital | 1.20M |
Cash Flow
Avenue Therapeutics, Inc. produced -1.08M in operating cash flow over the past twelve months.
| Operating Cash Flow | -1.08M |
| Capital Expenditures | N/A |
| Free Cash Flow | -1.08M |
| FCF Per Share | -0.34 |
Margins
Avenue Therapeutics, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -149.29 and net profit margin of -124.79 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -149.29 |
| Pretax Margin | -127.07 |
| Profit Margin | -124.79 |
| EBITDA Margin | -149.29 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | N/A |
| FCF Yield | -116.18 |
Stock Splits
Avenue Therapeutics, Inc.'s most recent stock split took place on April 26, 2024 with a 75:1 split ratio.
| Last Split Date | 4/26/2024 |
| Split Ratio | 75:1 |
Scores
Avenue Therapeutics, Inc. posts an Altman Z-Score of -61.44, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -61.44 |